Liquidia Gestione
Criteri Gestione verificati 4/4
Liquidia Il CEO è Roger Jeffs, nominato in Jan2022, e ha un mandato di 4.67 anni. la retribuzione annua totale è $ 7.71M, composta da 10.7% di stipendio e 89.3% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 2.06% delle azioni della società, per un valore di $ 127.24M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 3.2 anni e 6.9 anni.
Informazioni chiave
Roger Jeffs
Amministratore delegato
US$7.7m
Compenso totale
| Percentuale dello stipendio del CEO | 10.68% |
| Mandato del CEO | 4.7yrs |
| Proprietà del CEO | 2.1% |
| Durata media del management | 3.2yrs |
| Durata media del Consiglio di amministrazione | 6.9yrs |
Aggiornamenti recenti sulla gestione
Recent updates
LQDA: Legal Decisions Around Key Patents Will Drive Future Upside Potential
Analysts have lifted their fair value estimate for Liquidia from $72.38 to $107.75, citing stronger Yutrepia traction, higher long term earnings potential, and added upside optionality from L606 as key drivers behind the higher price targets across recent research updates. Analyst Commentary Recent Street research on Liquidia shows a mix of optimism around Yutrepia's commercial traction and longer term earnings potential, alongside caution on valuation and ongoing patent litigation.Liquidia: A Linear Launch Priced For Exponential Growth
Summary Liquidia Corporation is rated Sell due to YUTREPIA's decelerating growth and an overextended $6B+ valuation. YUTREPIA's percentage growth is compressing, prescriber acquisition has halved, and launch-era tailwinds are fading. Future growth will require difficult community penetration and overcoming structural headwinds from patient mortality and discontinuation. TPIP from Insmed poses a material long-term threat to LQDA's franchise, challenging assumptions of durable growth. Read the full article on Seeking Alpha
LQDA: Patent Rulings Will Shape Future Pulmonary Hypertension Earnings Power
Analysts have raised the fair value estimate for Liquidia stock from $60 to $90, citing higher Street price targets driven by strong Yutrepia uptake, growing market share, and additional long term optionality from L606, alongside ongoing legal and earnings considerations. Analyst Commentary Recent Street research on Liquidia points to a mixed but generally constructive tone.
LQDA: Future Patent Decisions Seen Driving Upside As Sentiment Turns More Positive
Analysts have lifted their fair value estimate for Liquidia stock from $102.99 to $130.00, reflecting updated assumptions on litigation outcomes around YUTREPIA and views that the drug could play a central role in treating PAH and PH-ILD if current legal and intellectual property questions are resolved in the company's favor. Analyst Commentary Recent Street research on Liquidia highlights a mix of optimism and caution that centers on litigation milestones, the commercial trajectory of YUTREPIA, and how these factors could influence the stock's valuation over time.LQDA: Pending Patent Outcomes Will Drive Future Earnings Upside Or Downside
Analysts lifted their fair value estimate for Liquidia to $60.00 from $16.99, citing higher Street price targets, stronger conviction in Yutrepia's potential positioning in PAH and PH-ILD, and updated assumptions around earnings power and legal outcomes. These changes are reflected in revised discount rate, margin, and future P/E inputs.LQDA: Legal Outcomes Around Key Patent Will Drive Future Upside
Analysts have lifted their implied fair value estimate for Liquidia from about $67.00 to roughly $103.00, citing updated models that reflect stronger expectations for Yutrepia, higher peak sales assumptions up to $2.2b, and legal outcomes that they view as better framed after recent court decisions. Some now prefer to wait for more clarity on key patent litigation before assuming further upside.LQDA: Legal Outcomes And Earnings Power Will Shape The Next Phase
Analysts have lifted the updated fair value estimate for Liquidia to $72.38 from $44.00, as higher assumed profit margins, a lower future P/E multiple, and evolving views on legal and earnings risk reshape their price target frameworks. Analyst Commentary Recent Street research on Liquidia highlights a mix of enthusiasm around potential earnings power and caution around legal outcomes, which together shape how analysts think about valuation and execution risk.Liquidia (LQDA) Stock Could Be 63.2% Overvalued After PHA 2026 YUTREPIA Update
Liquidia (LQDA) is back in focus after the company outlined four new poster presentations at the PHA 2026 International PH Conference, spotlighting fresh YUTREPIA data and broader pulmonary hypertension care insights. See our latest analysis for Liquidia. The PHA 2026 conference update comes at a time when Liquidia’s momentum has been strong, with a 30 day share price return of 26.12% and a 5 year total shareholder return of 2,737.94%. Together, these figures point to sentiment that has...Upgrade: Analysts Just Made A Captivating Increase To Their Liquidia Corporation (NASDAQ:LQDA) Forecasts
Shareholders in Liquidia Corporation ( NASDAQ:LQDA ) may be thrilled to learn that the analysts have just delivered a...Liquidia Corporation (NASDAQ:LQDA) Looks Just Right With A 30% Price Jump
Liquidia Corporation ( NASDAQ:LQDA ) shares have had a really impressive month, gaining 30% after a shaky period...Liquidia Corporation's Long-Running Saga Is Coming To An End
Summary Today, we are circling back on Liquidia Corporation, as its long-running litigation battle with United Therapeutics is finally coming to a positive end. This means we will likely see the full commercial launch of its primary candidate, YUTREPIA before the end of the second market. YUTREPIA is targeting a large potential market and could garner significant market share. An updated analysis around Liquidia Corporation follows in the paragraphs below. Read the full article on Seeking AlphaAnalisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Utili della società |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | US$139m |
| Mar 31 2026 | n/a | n/a | US$22m |
| Dec 31 2025 | US$8m | US$824k | -US$69m |
| Sep 30 2025 | n/a | n/a | -US$124m |
| Jun 30 2025 | n/a | n/a | -US$149m |
| Mar 31 2025 | n/a | n/a | -US$137m |
| Dec 31 2024 | US$7m | US$800k | -US$128m |
| Sep 30 2024 | n/a | n/a | -US$117m |
| Jun 30 2024 | n/a | n/a | -US$102m |
| Mar 31 2024 | n/a | n/a | -US$97m |
| Dec 31 2023 | US$5m | US$689k | -US$79m |
| Sep 30 2023 | n/a | n/a | -US$58m |
| Jun 30 2023 | n/a | n/a | -US$51m |
| Mar 31 2023 | n/a | n/a | -US$37m |
| Dec 31 2022 | US$11m | US$325k | -US$41m |
| Sep 30 2022 | n/a | n/a | -US$46m |
| Jun 30 2022 | n/a | n/a | -US$44m |
| Mar 31 2022 | n/a | n/a | -US$41m |
| Dec 31 2021 | US$93k | n/a | -US$35m |
| Sep 30 2021 | n/a | n/a | -US$39m |
| Jun 30 2021 | n/a | n/a | -US$47m |
| Mar 31 2021 | n/a | n/a | -US$54m |
| Dec 31 2020 | US$89k | n/a | -US$60m |
Compensazione vs Mercato: La retribuzione totale di Roger ($USD 7.71M ) è circa la media per le aziende di dimensioni simili nel mercato US ($USD 8.42M ).
Compensazione vs guadagni: La retribuzione di Roger è stata coerente con le performance aziendali dell'ultimo anno.
AMMINISTRATORE DELEGATO
Roger Jeffs (64 yo)
Dr. Roger A. Jeffs, Ph D., serves as Director at Liquidia Corporation (formerly known as Liquidia Technologies, Inc.) since November 2020 and serves as its Chief Executive Officer from January 3, 2022. He...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO & Director | 4.7yrs | US$7.71m | 2.06% $ 127.2m | |
| COO & CFO | 5.8yrs | US$4.16m | 0.39% $ 23.9m | |
| General Counsel & Corporate Secretary | 5.5yrs | US$3.67m | 0.52% $ 32.4m | |
| Chief Commercial Officer | 5.8yrs | US$2.68m | 0.086% $ 5.3m | |
| Chief Medical Officer | 4.2yrs | US$2.92m | 0.037% $ 2.3m | |
| Chief Accounting Officer | 1.2yrs | Nessun dato | 0.074% $ 4.6m | |
| Senior VP | 1.2yrs | Nessun dato | Nessun dato | |
| Senior Vice President of Marketing | 1.7yrs | Nessun dato | Nessun dato | |
| Senior Vice President of Sales | 1.7yrs | Nessun dato | Nessun dato | |
| Chief Human Resources Officer | 3.3yrs | Nessun dato | 0.017% $ 1.1m | |
| Chief Business Officer | 3.2yrs | Nessun dato | 0.097% $ 6.0m | |
| Senior Vice President of Manufacturing Operations | 2.7yrs | Nessun dato | Nessun dato |
Gestione esperta: Il team dirigenziale di LQDA è considerato esperto (durata media dell'incarico 3.2 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO & Director | 5.8yrs | US$7.71m | 2.06% $ 127.2m | |
| Independent Director | 10yrs | US$327.50k | 0.046% $ 2.8m | |
| Independent Director | 7yrs | US$315.00k | 0.038% $ 2.3m | |
| Independent Chairman | 17.2yrs | US$362.50k | 0.073% $ 4.5m | |
| Independent Director | 5.8yrs | US$305.00k | 5.14% $ 317.8m | |
| Independent Director | 5.4yrs | US$310.00k | 0% $ 0 | |
| Independent Director | 5.8yrs | US$303.62k | 0.097% $ 6.0m | |
| Independent Director | 8.6yrs | US$315.00k | 0.043% $ 2.7m | |
| Independent Director | 6.9yrs | US$312.50k | 0.043% $ 2.7m |
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di LQDA sono considerati esperti (durata media dell'incarico 6.9 anni).
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/09/10 23:35 |
| Prezzo dell'azione a fine giornata | 2026/09/10 00:00 |
| Utili | 2026/06/30 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Liquidia Corporation è coperta da 15 analisti. 7 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Jason Matthew Gerberry | BofA Global Research |
| Julian Harrison | BTIG |
| Andrew Fein | H.C. Wainwright & Co. |